All In Biotech

Drug Trial Radar · NCT04595942

Midodrine and Fludrocortisone for Vasovagal Syncope

Comparison of Outcomes With Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS Trial)

Last checked: Nov 20, 2026Latest source record: Apr 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 1,375 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,375

Planned (sponsor's estimate)

Start

Nov 19, 2020

Primary completion

Oct 2023

Study completion Dec 2023

Sponsor

Lead sponsor
Tehran Heart CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Mahidol University; Rajaie Cardiovascular Medical and Research Center; Tehran Arrhythmia Center; Imam Khomeini Hospital; AJA University of Medical Sciences; Urmia University of Medical Sciences; Isfahan University of Medical Sciences; Shahid Beheshti University of Medical Sciences; Ahvaz Jundishapur University of Medical Sciences
First posted
Oct 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Syncope is a common condition which can disturb daily functions of the patients and impair their quality of lives. It contributes to 0.8 to 2.4% of the visits of emergency rooms. Noticeably, studies demonstrated that the lifetime prevalence of syncope is as high as 41% with a 13.5% recurrence rate. The cornerstone of the treatment of vasovagal syncope (VVS), the most common type of syncope, is lifestyle modifications and patient education to avoid potential triggers of syncope. These recommendations alleviate vasovagal spells in many patients; however, some patients experience life-disturbing vasovagal attacks despite compliance with these modifications. This fact underscores the importance of efficient pharmacological interventions as well. Currently, there is an ongoing controversy about the efficacy of midodrine and fludrocortisone as adjunct pharmacological interventions for the prevention of VVS. In the COMFORTS trial, we are going to evaluate the efficacy of midodrine, fludrocortisone, and lifestyle modifications for prevention of vasovagal attacks in patients with VVS.

Conditions

  • Syncope, Vasovagal

Interventions

  • Midodrine Hydrochloride TabletsDrug

    Patients will be started on 5 mg Midodrine three times a day and after one week the dosage will be up-titrated to 10 mg three times a day and continued for 12 months. They will receive the medication at four-hour intervals upon rising in the morning (the last dose should not be taken later than 6 PM). In case of intolerance, the dosage will be reduced to 2.5 mg three times a day. Patients will also receive recommendations for lifestyle modifications including drinking 2 to 3 liters of fluid per day, daily consumption of 10 grams of salt, and practicing counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting).

  • Fludrocortisone Acetate TabletsDrug

    Patients will be started on 0.05 mg of fludrocortisone twice daily and after one week the dosage will be up-titrated to 0.1 mg fludrocortisone twice daily taken for 12 months. Patients will also receive recommendations for lifestyle modifications including drinking 2 to 3 liters of fluid per day, daily consumption of 10 grams of salt, and practicing counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting). In this arm, potassium levels will be checked 7-14 days after dose stabilization.

  • Lifestyle modificationBehavioral

    Patients will be recommended to drink 2 to 3 liters of fluid per day, consume 10 grams of salt per day, and practice counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting) for 12 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first episode of syncopeTime frame: The follow-up continues for 12 months after randomization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tehran Heart Center

    Tehran, Iran · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.